⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Darbepoetin alfa

داربپوئتین آلفا

⚠ Unverified

🩸 Blood And Blood Forming OrgansLong-acting erythropoiesis-stimulating agent

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Registered in Iran ⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA103951 ATC B03XA02

Market / country: 🇺🇸 USA

Aranesp (US)

🧮 Dose calculator

Disease / regimen

Anaemia of chronic kidney disease · Regimen source: FDA Aranesp · 2.2

• Do not target haemoglobin >11 g/dL; lowest dose to reduce transfusions. Check iron first (supplement if ferritin <100 or saturation <20%). FDA Aranesp · 2.2 FDA Aranesp · 2.1

Formulation

Age *

Weight (kg) *

Enter age and weight.

🛡️ Safety & information

Contraindications

⛔ Uncontrolled hypertension; pure red cell aplasia after ESA therapy; serious allergic reactions. FDA Aranesp · 4

Warnings

• Boxed warning: increased death, MI, stroke, thrombosis and tumour progression; in cancer only for myelosuppressive-chemotherapy anaemia, not curative intent. Hypertension; seizures. FDA Aranesp · Boxed Warning FDA Aranesp · 5

Formulations

40 mcg/0.4 mL prefilled syringe — injection 🇺🇸 USA FDA Aranesp · 3
100 mcg/0.5 mL prefilled syringe — injection 🇺🇸 USA FDA Aranesp · 3
500 mcg/1 mL prefilled syringe — injection 🇺🇸 USA FDA Aranesp · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Aranesp · 8.1
“Risk Summary The limited available data on Aranesp use in pregnant women are insufficient to determine a drug-associated risk of major birth defects or miscarriage.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Aranesp · 8.2
“Risk Summary There is no information regarding the presence of Aranesp in human milk, the effects on the breastfed child, or the effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Aranesp · 8.4
“Pediatric Patients with CKD The safety and effectiveness of Aranesp in pediatric patients with CKD receiving and not receiving dialysis have been established in the age groups 1 month to 16 years old.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Aranesp · 8.5
“Of the 1801 patients with CKD in clinical studies of Aranesp, 44% were age 65 and over, while 17% were age 75 and over.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)BLA103951
DailyMed (FDA label)FDA Aranesp
MedlinePlus (NIH)Darbepoetin Alfa Injection
WHO ATC/DDDB03XA02
Darooyab (Iran)Darbepoetin-Alfa

🇮🇷 Registered in Iran Darooyab · G-1386/Darbepoetin-Alfa

Dosage forms with Iranian generic codes, per Darooyab.

18988 · ARANESP 100MCG VIAL · ویال آرانسپ ۱۰۰ میکروگرم

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Aranesp · 3 FDA Aranesp · 2.2 FDA Aranesp · 2.1 FDA Aranesp · 2 FDA Aranesp · 2.3 FDA Aranesp · 4 FDA Aranesp · Boxed Warning FDA Aranesp · 5 FDA Aranesp · SPL approval / marketing category FDA Aranesp · 8.1 FDA Aranesp · 8.2 FDA Aranesp · 8.4 FDA Aranesp · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-1386/Darbepoetin-Alfa
Clinical review⚠ Unverified

🔗 Similar drugs

For the same diseases

Epoetin alfa (erythropoietin)Iron sucrose (Venofer)